Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
Public ClinicalTrials.gov record NCT00965731. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/2, Open Label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Erlotinib With Or Without Pf 02341066 In Patients With Advanced Non Small Cell Adenocarcinoma Of The Lung.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1/2 study comparing the safety and anti-tumor activity of erlotinib alone versus erlotinib in combination with PF-02341066 in patients with advanced non-small cell lung cancer.
Study identification
- NCT ID
- NCT00965731
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 27 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2009
- Primary completion
- Nov 30, 2011
- Completion
- Dec 31, 2013
- Last update posted
- Oct 27, 2015
2010 – 2014
United States locations
- U.S. sites
- 16
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| University of California, Irvine Medical Center Pharmacy | Orange | California | 92868-3298 | — |
| University of California, Irving - Medical Center | Orange | California | 92868-3298 | — |
| University of California Irvin | Orange | California | 92868 | — |
| Holy Cross Hospital | Fort Lauderdale | Florida | 33308 | — |
| Siteman Cancer Center | City of Saint Peters | Missouri | 63376 | — |
| Siteman Cancer Center -West County | Creve Coeur | Missouri | 63141 | — |
| Barnes-Jewish Hospital | St Louis | Missouri | 63110-1094 | — |
| Washington University, School of Medicine | St Louis | Missouri | 63110 | — |
| OSU East | Columbus | Ohio | 43205 | — |
| The Ohio State University James Cancer Hospital | Columbus | Ohio | 43210 | — |
| James Care in Kenny | Columbus | Ohio | 43221 | — |
| Cancer Therapy & Research Center @ UTHSCSA | San Antonio | Texas | 78229 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| University of Washington Medical Center | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00965731, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 27, 2015 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00965731 live on ClinicalTrials.gov.